Allogene Therapeutics Reports Q3 2026 Financial Results and Clinical Trial Updates
Allogene Therapeutics (ALLO) reported its third-quarter 2026 financial results, highlighting a net loss of $50.4 million ($0.15 per share) driven by ongoing clinical trial investments. The company maintains a strong liquidity position with $388.9 million in cash, cash equivalents, and investments, providing a projected runway into 2029. On the clinical front, Allogene is advancing its allogeneic CAR T portfolio, specifically focusing on the ALPHA3 trial for cema-cel and the RESOLUTION trial for ALLO-329. Management noted brisk enrollment activity in the Asia-Pacific region and plans to expand site participation into community oncology practices. Key data updates are expected mid-2027 for ALPHA3 and at upcoming medical meetings for ALLO-329.
Tickers: $ALLO
Topics: cash runway clinical trials earnings report financial guidance